Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
Crossref DOI link: https://doi.org/10.1007/s13300-019-0638-y
Published Online: 2019-05-31
Published Print: 2019-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gæde, Peter
Johansen, Pierre
Tikkanen, Christian Klyver
Pollock, Richard Fulton
Hunt, Barnaby
Malkin, Samuel Joseph Paul
Article History
First Online: 31 May 2019